<DOC>
	<DOCNO>NCT00003984</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody therapy treat patient primary myelodysplastic syndrome .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Primary Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I. Assess therapeutic activity monoclonal antibody HuG1-M195 peripheral blood bone marrow blast cell count , blood leukocyte , reticulocyte , platelet count , hemoglobin level patient myelodysplastic syndrome refractory anemia excess blast ( RAEB ) ( great 10 % bone marrow myeloblast ) RAEB transformation . II . Assess efficacy drug term duration response patient . III . Evaluate toxicity drug patient . OUTLINE : Patients receive monoclonal antibody HuG1-M195 IV 4 hour day 1-4 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Patients progressive disease 2 course remove study . Patients stable disease receive treatment 4 course . Patients complete partial response receive treatment 4 additional course . Patients follow 11 39 day end course 4 , monthly 4 month , every 3 month thereafter 1 year study entry . PROJECTED ACCRUAL : A total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary myelodysplastic syndrome ( MDS ) great 10 % bone marrow blast Refractory anemia excess blast ( RAEB ) OR RAEB transformation No chronic myelomonocytic leukemia No secondary MDS prior chemotherapy except treatment acute myeloid leukemia No allogeneic bone marrow transplantation plan PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Hemoglobin great 10 g/dL OR transfusion requirement least 3 pack RBCs per month OR Platelet count le 50,000/mm3 OR Absolute neutrophil count le 1,000/mm3 No disseminate intravascular coagulation define fibrinogen le 100 mg/dL AND prolonged PT , PTT , thrombin time AND platelet count le 25,000/mm3 without transfusion Hepatic : Bilirubin great 2.0 mg/dL Alkaline phosphatase great 4 time upper limit normal ( ULN ) ( unless due underlie disease Gilbert 's syndrome ) SGPT SGOT great 4 time ULN ( unless due underlie disease Gilbert 's syndrome ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : No uncontrolled hypertension No congestive heart failure , cardiac arrhythmia , angina pectoris No history myocardial infarction within past 6 month No significant cardiovascular disease LVEF within normal range MUGA echocardiogram No active ischemia Pulmonary : No pulmonary dysfunction Other : No central peripheral neuropathy No uncontrolled unstable diabetes No significant organ system dysfunction HIV negative No prior malignancy except basal cell carcinoma carcinoma situ uterus No active , uncontrolled infection Not pregnant nursing Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 2 month since prior biologic therapy ( e.g. , hematopoietic growth factor biological response modifier ) Chemotherapy : See Disease Characteristics At least 2 month since prior chemotherapy Endocrine therapy : At least 2 month since prior endocrine therapy Radiotherapy : At least 2 month since prior radiotherapy Concurrent radiotherapy allow Surgery : At least 2 month since prior surgery Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>